New Immune-Boosting drug TQB2934 enters early human trials for blood cancer

NCT ID NCT07179679

Recruiting now Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called TQB2934 in 42 people with multiple myeloma, a type of blood cancer. TQB2934 is a bispecific antibody designed to help the body's T cells recognize and kill cancer cells. The main goals are to check the drug's safety and how it moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB2934 (a bispecific antibody that helps immune cells attack cancer cells)
What this could lead to: If successful, this could lead to a new treatment option for multiple myeloma that uses the body's own immune system to fight the cancer.
What could go wrong: This is a very early (Phase 1) trial with only 42 people, so it is primarily checking safety and dosing. The drug may not work well or could cause side effects like immune overactivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Affiliated Hospital of North Sichuan Medical College
NOT_YET_RECRUITING

Nanchong, Sichuan, 637000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chongqing University Cancer Hospital
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, 400030, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Guangdong Provincial People's Hospital
NOT_YET_RECRUITING

Guangzhou, Guangdong, 519041, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Heze Municipal Hospital
NOT_YET_RECRUITING

Heze, Shandong, 27400, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Jiangsu Province Hospital
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210029, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Nanchang University First Affiliated Hospital
NOT_YET_RECRUITING

Nanchang, Jiangxi, 330006, China

Contact Phone: •••-•••-••••
Nanfang Hospital, Southern Medical University
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510515, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Nanjing Drum Tower hospital
RECRUITING

Nanjing, Jiangsu, 210008, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
North China University of Science and Technology Affiliated Hospital
NOT_YET_RECRUITING

Tangshan, Hebei, 063000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Affiliated Hospital of Chengde Medical College
NOT_YET_RECRUITING

Chengde, Hebei, 67000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xi'an, Shaanxi, 710061, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Second Affiliated Hospital of Soochow University
NOT_YET_RECRUITING

Suzhou, Jiangsu, 215000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Tianjin People's Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300192, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhongshan Hospital of Fudan University
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.